High density lipoproteins and coronary heart disease

Atherosclerosis

Volumn 121, Issue 1, 1996, Pages 1-12

  Barter, P J ^a   Rye, K A ^a  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

Atherosclerosis; Coronary heart disease; High density lipoproteins

Indexed keywords

HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; HUMAN; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

EID: 0030045883     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/0021-9150(95)05675-0     Document Type: Review

References (97)

1. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease: the Framingham Study. Am. J. Med. 1977;62:707.
2. Miller NE, Forde OH, Thelle DS, Mjos OD. The Tromso Heart Study: high-density lipoprotein and coronary heart disease: a prospective case-control study. Lancet 1977;1:965.
3. Goldbourt U, Medalie JH. High density lipoprotein cholesterol and incidence of coronary heart disease: the Israeli Ischemic Heart Disease Study. Am J Epidemiol 1979;109:296.
4. Enger SC, Hjermann I, Foss OP et al. High density lipoprotein cholesterol and myocardial infarction or sudden death: a prospective case-control study in middle-aged men of the Oslo Study. Artery 1979;5:170.
5. Keys A. Alpha lipoprotein (HDL) cholesterol in the serum and the risk of coronary heart disease and death. Lancet 1980;2:603.
6. Yaari S, Goldbourt U, Even-Zohar ST, Neufeld HN. Serum high density lipoprotein and total cholesterol with total cardiovascular, cancer mortality in a 7-year prospective study of 10,000 men. Lancet 1981;1:1011.
7. Abbott RD, Wilson PWF, Kannel WB, Castelli WP. High density lipoprotein cholesterol, total cholesterol screening, myocardial infarction. Arteriosclerosis 1988;8:207.
8. Gordon DJ, Probstfield JL, Garrison RJ et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989;79:8.
9. Jacobs DR Jr, Mebane IL, Bangdiwala SI, Criqui MH, Tyroler HA. High density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women: the follow-up study of the Lipid Research Clinics Prevalence Study. Am J Epidemiol 1990;131:32.
10. Kitamura A, Iso H, Naito Y et al. High-density lipoprotein cholesterol and premature coronary heart disease in urban Japanese men. Circulation 1994;89:2533.
11. Blanche PJ, Gong EL, Forte TM, Nichols AV. Characterization of human high-density lipoproteins by gradient gel electrophoresis. Biochim Biophys Acta 1981;665:408.
12. Cheung M, Albers JJ. Characterization of lipoprotein particles by immunoaffinity chromatography: particles containing A-I and A-II and particles containing A-I but no A-II. J Biol Chem 1984;259:12 201.
13. Neary R, Bhatnagar D, Durrington P et al. An investigation of the role of lecithin:cholesterol acyltransferase and triglyceride-rich lipoproteins in the metabolism of pre-beta high density lipoproteins. Atherosclerosis 1991;89:35.
14. Castro G, Fielding CJ. Early incorporation of cell-derived cholesterol into pre-β-migrating high density lipoprotein. Biochemistry 1988;27:25.
15. Barter PJ, Hopkins GJ, Gorjatschko L. Lipoprotein substrates for plasma cholesterol esterification: influence of particle size and composition of the high density lipoprotein subfraction-3. Atherosclerosis 1985;58:97.
16. Ikeda Y, Ohta T, Matsuda I. Interaction between apo A-I-containing lipoproteins and lecithin:cholesterol acyltransferase. Biochim Biophys Acta 1994;1215:307.
17. Pekkanen J, Linn S, Heiss G et al. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med 1990;322:1700.
18. Miller M, Seidler A, Kwiteroyich PO, Pearson TA. Long-term predictors of subsequent cardiovascular events with coronary artery disease and 'desirable' levels of plasma total cholesterol. Circulation 1992;86:1165.
19. Genest JJ Jr, Martin-Munley SS, McNamara JR et al. Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation 1992;85:2025.
20. Genest J Jr, Bard J-M, Fruchart J-C, Ordovas JM, Schaefer RJ. Familial hypoalphalipoproteinemia in premature coronary artery disease. Arteriosclerosis Thromb 1993;13:1728.
21. Wilson PWF, Abbott RD, Castelli WP. High density lipoprotein cholesterol and mortality. The Framingham Heart Study. Arteriosclerosis 1988;8:737.
22. Schaefer EJ. Clinical, biochemical, genetic features in familial disorders of high density lipoprotien deficiency. Arteriosclerosis 1984;4:303.
23. Assman G, Schmitz G, Funke H, von Eckardstein A. Apolipoprotein A-I and HDL deficiency. Curr Opin Lipidol 1990;1:110.
24. Serfaty-Lacrosneire C, Civeira F, Lanzberg A. Homozygous Tangier disease and cardiovascular disease. Atherosclerosis 1994;107:85.
25. Rader DJ, Ikewaki K, Duverger N et al. Markedly accelerated catabolism of apolipoprotein A-II (ApoA-II) and high density lipoproteins containing ApoA-II in classic lecithin: cholesterol acyltransferase deficiency and fish-eye disease. J Clin Invest 1994;93:321.
26. Reaven GM. Insulin resistance and compensatory hyperinsulinemia: role in hypertension, dyslipidemia, coronary heart disease. Am Heart J 1991;121:1283.
27. Hargreaves AD, Logan RL, Elton RA et al. Glucose tolerance, plasma insulin, HDL cholesterol and obesity: 12-year follow-up and development of coronary heart disease in Edinburgh men. Atherosclerosis 1992;94:61.
28. Howard BV. Lipoprotein metabolism in diabetes mellitus. J Lipid Res 1987;28:613.
29. Kannel WB. Lipids, diabetes and coronary heart disease: insights from the Framingham Study. Am Heart J 1985;110:1100.
30. Goldstein JL, Schrott HG, Hazzood WR, Bierman EL, Motulsky AG. Hyperlipidemia in coronary heart disease, II: genetic analysis of a new inherited disorder, combined hyperlipidaemia. J Clin Invest 1973;52:1544.
31. Grundy SM, Chait A, Brunzell JD. Familial combined hyperlipidemia workshop. Arteriosclerosis 1987;7:203.
32. Brunzell JD, Albers JJ, Chait A et al. Plasma lipoproteins in familial combined hyperlipidaemia and monogenic familial hypertriglyceridemia. J Lipid Res 1983;24:147.
33. Brunzell JD, Schrott HG, Motulsky DG, Bierman EL. Myocardial infarction in the familial forms of hypertriglyceridemia. Metabolism 1976;25:313.
34. Sprecher DL, Feigelson HS, Laskarzewski PM. The low HDL cholesterol/high triglyceride trait. Arteriosclerosis Thromb 1993;13:495.
35. Avogaro P, Ghisellii G, Soldan S, Bon GB. Relationship of triglycerides and HDL cholesterol in hypertriglyceridemia. Atherosclerosis 1992;92:79.
36. Griqui MH, Wallace RB, Heiss G et al. Cigarette smoking and plasma high density lipoprotein cholesterol. The Lipid Research Clinics' Program Prevalence Study. Circulation 1980;62:SIV,70.
37. Katan M. Diet and HDL. In: Miller NE, Miller GJ. (eds). Clinical and Metabolic Aspects of High-density Lipoproteins. Elsevier, Amsterdam, 1984;103.
38. LeLorier J, DuBrevil-Quidoz S, Lussier-Cacon S, Yung-Shan H, Davignon J. Diet and probucol in lowering cholesterol concentrations. Arch Intern Med 1977;137:1429.
39. England JDF, Simons LA, Gibson JC, Carlton M. The effect of metoprolol and atenolol on plasma high density lipoprotein levels in man. Clin Exp Pharmacol Physiol 1980;7:329.
40. Li H, Reddick RL, Maeda N. Lack of ApoA-I is not associated with increased susceptibility to atherosclerosis in mice. Arteriosclerosis Thromb 1993;13:1814.
41. Austin MA. Plasma triglyceride and coronary heart disease. Arteriosclerosis Thromb 1991;11:2.
42. Austin MA, Breslow JL, Hennekens CH et al. Low-density lipoprotein subclass patterns and risk of myocardial infarction. J Am Med Assoc 1988;260:1917.
43. Steiner G, Schwartz L, Schumak S, Poapst M. The association of increased levels of intermediate-density lipoproteins with smoking and with coronary artery disease. Circulation 1987;75:124.
44. Tatami R, Mabuchi H, Ueda K et al. Intermediate-density lipoprotein and cholesterol-rich very low density lipoprotein in angiographically determined coronary artery disease. Circulation 1981;64:1174.
45. Reardon MF, Nestel P, Craig IH, Harper RW. Lipoprotein predictors of the severity of coronary artery disease in men and women. Circulation 1985;71:881.
46. Krauss RM, Lindgren FT, Williams PT et al. Intermediate-density lipoproteins and progression of coronary artery disease in hypercholesterolaemic men. Lancet 1987;1:62.
47. Rubin EM, Krauss RM, Spangler EA, Verstuyft JG, Clift SM. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein Al. Nature 1991;353:265.
48. Paszty C, Maeda N, Verstuyft J, Rubin EM. Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice. J Clin Invest 1994;94:899.
49. Plump AS, Scott CJ, Breslow JL. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc Natl Acad Sci USA 1994;91:9607.
50. Badimon JJ, Badimon L, Fuster V. Regression of atherosclerotic lesions by high density lipoprotein-plasma fraction in the cholesterol-fed rabbit. J Clin Invest 1990;85:1234.
51. Charo IF. Monocyte-endothelial cell interactions. Curr Sci 1992;3:335.
52. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witzum JL. Beyond cholesterol: modifications of low density lipoprotein that increase its atherogenicity. N Engl J Med 1989;320:915.
53. Navab M, Imes SS, Hama SY et al. Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein I synthesis and is abolished by high density lipoprotein. J Clin Invest 1991;88:2039.
54. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362:801.
55. Nathan CF. Secretory products of macrophages. J Clin Invest 1987;79:319.
56. Springer TA. Adhesion receptors of the immune system. Nature 1990;346:425.
57. Ross R, Agius L. The process of atherogenesis - cellular and molecular interactions: from experimental animal models to humans. Diabetologia 1992;35(S2):34.
58. Fielding CJ, Fielding PE. Molecular physiology of reverse cholesterol transport. J Lipid Res 1995;36:211.
59. Miyazaki A, Rahim ATMA, Ohta T et al. High density lipoprotein mediates selective reduction in cholesteryl esters from macrophage foam cells. Biochim Biophys Acta 1992;1126:73.
60. de la Llera Moya M, Alger V, Paul JL et al. A cell culture system for screening human serum for ability to promote cellular cholesterol efflux. Relations between serum components and efflux, esterification, and transfer. Arteriosclerosis Thromb 1994;14:1056.
61. Barter PJ. High-density lipoproteins and reverse cholesterol transport. Curr Opin Lipidol 1993;4:210.
62. Castro GR, Fielding CJ. Early incorporation of cell-derived cholesterol into pre-β-migrating high-density lipoprotein. Biochemistry 1988;27;25.
63. Asztalos BF, Sloop CH, Wong L, Roheim PS. Comparison of apo A-I-containing subpopulations of dog plasma and prenodal peripheral lymph: evidence for alteration in subpopulations in the interstitial size. Biochim Biophys Acta 1993;1169:301.
64. Ishida BY, Frolich J, Fielding CJ. Prebeta migrating high density lipoproteins: quantitation in normal and hyperlipidemic plasma by solid phase radioimmunoassay following elelctrophoretic transfer. J Lipid Res 1987;28:778.
65. Kunitake ST, Mendel CM, Hennessy LK. Interconversion between apolipoprotein A-I-containing lipoproteins of pre-beta and alpha electrophoretic mobilities. J Lipid Res 1992;33:1807.
66. Marotti KR, Castle CK, Murray RW et al. The role of cholesteryl ester transfer protein in primate apolipoprotein A-I metabolism. Insights from studies with transgenic mice. Arteriosclerosis Thromb 1992;12:736.
67. Glomset JA. The plasma lecithin:cholesterol acyltransferase reaction. J Lipid Res 1968;9:155.
68. Wallentin L, Vikrot O. Lecithin:cholesterol acyl transfer in plasma of normal persons in relation to lipid and lipoprotein concentration. Scand J Clin Lab Invest 1975;35:669.
69. Nestel PJ, Monger EA. Turnover of plasma esterified cholesterol in normocholesterolemic and hypercholesterolemic subjects and its relation to body build. J Clin Invest 1967;46:967.
70. Tauber J-P, Cheng J, Gospodarowicz D. Effect of high and low density lipoproteins on proliferation of cultured bovine vascular endothelial cells. J Clin Invest 1980;66:696.
71. Levine DM, Parker TS, Donnelly TM, Walsh A, Rubin AL. In vivo protection against endotoxin by high-density lipoprotein. Proc Natl Acad Sci USA 1993;90:12040.
72. Epand RM, Stafford A, Leon B et al. HDL and apolipoprotein A-I protect erythrocytes against the generation of procoagulant activity. Arteriosclerosis Thromb 1994;14:1775.
73. Zeiher AM, Schachinger V, Hohnloser SH. Coronary atherosclerotic wall thickening and vascular reactivity in humans. Elevated high-density lipoprotein levels ameliorate abnormal vasoconstriction in early atherosclerosis. Circulation 1994;89:2525.
74. Ko Y, Haring R, Stiebler H et al. High-density lipoprotein reduces epidermal growth factor-induced DNA synthesis in vascular smooth muscle cells. Atherosclerosis 1993;99:253.
75. Fleisher LN, Tall AR, Witte LD, Muller RW, Cannon PJ. Stimulation of arterial endothelial cell prostacyclin synthesis by high density lipoproteins. J Biol Chem 1982;257:6653.
76. Yui Y, Aoyama T, Morishita H et al. Serum prostacyclin stabilising factor is identical to apolipoprotein A-I (apo A-I). J Clin Invest 1988;82:803.
77. Parthasarathy S, Barnett J, Fong DS. High density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochim Biophys Acta 1990;1044:275.
78. Maier JAM, Barenghi L, Pagani F et al. The protective role of high-densty lipoprotein on oxidized-low-density-lipoprotein-induced U937/ endothelial cell interactions. Eur J Biochem 1994;221:35.
79. Cockerill GW, Rye KA, Gamble JR, Vadas MA, Barter PJ. High density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler Thromb Vasc Biol 1995;15:1987.
80. Decossin C, Tailleux A, Fruchart J-C, Fievet C. Prevention of in vitro low-denstiy lipoprotein oxidation by an albumin-containing Lp A-I subfraction. Biochim Biophys Acta 1995;1255:31.
81. Klimov AN, Gurevich VS, Nikiforova AA et al. Antioxidative activity of high denstiy lipoproteins in vivo. Atherosclerosis 1993;100:13.
82. Mackness MI, Arrol S, Abbott CA, Durrington PN. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 1993;104:129.
83. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low density lipoproteins. FEBS Lett 1991;286:152.
84. Miller NE. Associations of high-density lipoprotein subclasses and apolipoproteins with ischemic heart disease and coronary atherosclerosis. Am Heart J 1987;113:589.
85. Robinson D, Ferns GA, Bevan EA et al. High density lipoprotein subfractions and coronary risk factors in normal men. Arteriosclerosis 1987;7:341.
86. Johansson J, Carlson LA, Landou C, Hamsten A. High density lipoproteins and coronary atherosclerosis. A strong inverse relation with the largest particles is confined to normotriglyceridemic patients. Arteriosclerosis Thromb 1991;11:174.
87. 3 cholesterol, Apo A-I and Apo A-II, and increased risk of myocardial infarction. Circulation 1992;85:22.
88. Stamper MJ, Sacks FM, Salvini S et al. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med 1991;325:373.
89. Amouyel P, Isorez D, Bard J-M et al. Parenteral history of early myocardial infarction is associated with decreased levels of lipoparticle AI in adolescents. Arteriosclerosis Thromb 1993;13:13.
90. Schultz JR, Verstuyft JG, Gong EL, Nichols AV, Rubin EM. Protein composition determines the anti-atherogenic properties of HDL in transgenic mice. Nature 1993;365:762.
91. Schultz JR, Rubin EM. The properties of HDL in genetically engineered mice. Curr Opin Lipidol 1994;5:126.
92. Warden CH, Hedrick CC, Qiao J-H, Castellani LW, Lusis AJ. Atherosclerosis in transgenic mice overexpressing apolipoprotein A-II. Science 1993;261:469.
93. Gordon DJ, Knoke J, Probstfield JL, Superbo R, Tyroler HA. High density lipoprotein cholesterol and coronary heart disease in hypercholesterolemic men: the Lipid Research Clinics Primary Prevention Trial. Circulation 1986;74:1217.
94. Manninen V, Elo O, Frick MH et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. J Am Med Assoc 1988;260:641.
95. Brown G, Albers JJ, Fisher LD et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990;323:1289.
96. Mack WJ, Blankenhorn DH. Factors influencing the formation of new human coronary lesions: age, blood pressure and blood cholesterol. Am J Public Health 1991;81:1180.
97. Manninen V, Tenkanen L, Koskinen P et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 1992;85:37.